On October 30, 2024 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, reported four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024 (Press release, Arcus Biosciences, OCT 30, 2024, View Source [SID1234647556]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A late-breaking poster presented by Melissa L. Johnson, M.D., director, lung cancer research, Sarah Cannon Research Institute, will highlight safety and efficacy data, including objective response rate, progression-free survival and overall survival from ARC-10. This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab or chemotherapy, in patients with front-line locally advanced or metastatic squamous or non-squamous NSCLC with a PD-L1 tumor proportion score of ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. ARC-10 was initially initiated and conducted as a randomized Phase 3 trial; the protocol was subsequently amended to evaluate domvanalimab plus zimberelimab versus pembrolizumab. The study was conducted in partnership with Gilead Sciences.

"The ARC-10 late-breaking poster will include the first overall survival results to be reported for the combination of domvanalimab and zimberelimab, and further build on the evidence that an Fc-silent anti-TIGIT antibody may provide differentiated efficacy and safety relative to the Fc-enabled anti-TIGIT antibodies," said Terry Rosen, Ph.D., chief executive officer of Arcus.

Four Accepted Abstracts Will Be Presented

Study

Title

Abstract Number

Session Type

Session Date & Time

Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody)

ARC-10

Randomized Study of Domvanalimab Combined with Zimberelimab in Front-Line, PD-L1 High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Results from ARC-10

1461

Late-Breaking Poster Session

11/8/2024, 9:00 AM – 7:00 PM CST

Investigator Sponsored Trial

Dual TIGIT and PD-1 Blockade With Domvanalimab Plus Zimberelimab in Hepatocellular Carcinoma Refractory to Anti-PD-1 Therapies

603

Oral Presentation, Concurrent Session 107c: Timing and Combination of Systemic Therapies in Solid Cancers

11/8/2024, 3:50 PM – 5:25 PM CST

TIGIT Blockade by Monoclonal Antibodies Promotes T Cell Activation and Anti-Tumor Activity That is Not Dependent on a Functionalized Fc Domain

507

Poster Session

11/8/2024, 9:00 AM – 7:00 PM CST

Etrumadenant (A2a/A2b receptor antagonist)

ARC-9

The Adenosine Receptor Antagonist Etrumadenant Reduces Tumor Adenosine-Regulated NR4A Gene Expression and Increases mCRC Inflammation in Patients from the ARC-9 Trial

52

Poster Session

11/9/2024, 9:00 AM – 8:30 PM CST